LifeMD, Inc.
About LifeMD, Inc.
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $194.1M
- Net income
- $14.4M
- Total assets
- $70.4M
- Market cap
- $236.5M
- Gross margin
- 85.7%
- Operating margin
- -4.0%
- Net margin
- 8.0%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $194.1M
- Cost of revenue
- $27.7M
- Gross profit
- $166.3M
- Operating expenses
- $174.0M
- Operating income
- -$7.7M
- Income tax
- $45.7K
- Net income
- $15.6M
- EPS (basic)
- $0.25
- EPS (diluted)
- $0.25
Balance sheet
- Total assets
- $70.4M
- Current assets
- $51.8M
- Total liabilities
- $47.3M
- Current liabilities
- $41.6M
- Shareholders’ equity
- $23.2M
Cash flow
- Operating cash flow
- $8.3M
- Investing cash flow
- $6.9M
- Financing cash flow
- -$13.4M
- Net cash flow
- $1.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $236.5M
- P/E ratio
- 20.1
- EPS (diluted)
- $0.25
- Shares outstanding
- 47.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 1, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $14.4M in FY2025.
- Revenue grew 109% from FY2021 to FY2025.
- Gross margin of 85.7%, net margin 8.0%.
- Trading 67% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 20.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LifeMD, Inc..
Write a review
News about LifeMD, Inc.
News & sentiment via Polygon.io
